Zealand starts second Phase III of dasiglucagon for severe hypoglycemia

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) began a second Phase III trial to evaluate dasiglucagon

Read the full 148 word article

User Sign In